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2014;63:2852–61) ª 2014 by the American College of Cardiology FoundationAortic valve sclerosis (ASc) is thickening and/or calciﬁcation
of the aortic valve without signiﬁcant obstruction of ﬂow and
is a common ﬁnding in older men and women. A proportion
of people with ASc progress to hemodynamically signiﬁcant
calciﬁc aortic valve disease (CAVD), which is then called
aortic stenosis (AS).
ASc is, by its nature, asymptomatic and is diagnosed by
cardiac imaging with either echocardiography or computed
tomography (CT). In general, diagnosis of ASc on echo-
cardiography relies on a subjective assessment of focal or
diffuse aortic valve thickening with or without increased
echogenicity (suggestive of calciﬁcation) but with relatively
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, 2013; revised manuscript received March 6,effect, which is usually indicated by a maximal transvalvular
velocity of <2 to 2.5 m/s (1).
The subjective and primarily qualitative nature of the
echocardiographic diagnosis of ASc (which is subject to
errors attributable to operator experience, gain settings, and
harmonic imaging) led to the search for more quantitative
and objective measures of early CAVD. A quantitative
technique developed on the basis of transthoracic echocar-
diography (TTE) is direct measurement of the ultrasonic
backscatter of the valve (2). However, the most widely used
quantitative measure of CAVD is aortic valve calciﬁcation
(AVC) as measured by CT. Using different CT techniques,
AVC, measured in Agatston units, has been shown to have a
strong linear correlation with calcium weight in explanted
aortic valves as well as a deﬁnite and nonlinear correlation
with aortic valve area and maximal transvalvular aortic
gradient in patients with both normal and depressed ejection
fraction (3–6).
Another area of contention is the signiﬁcance of the
valvular lesion. ASc is associated with traditional cardio-
vascular risk factors (7). Whether ASc is a marker of a purely
valvular disease or generalized vascular disease is currently
under debate; some studies have shown an increased risk of
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2853cardiovascular events in people with ASc (8), whereas
others have shown that many of these risks are reduced or
eliminated once other risk factors for cardiovascular events
are taken into account (9).
To help resolve these issues, we performed a systematic
review to examine the epidemiology of ASc in the general
population. In particular, we wished to determine the
prevalence, incidence, and rate of progression of ASc and to
combine estimates of the risk of adverse events.
Methods
We followed the Meta-analysis of Observational Studies in
Epidemiology (MOOSE) guidelines for reporting the sys-
tematic review (10).
Search strategy. The search strategy was designed pro-
spectively. MEDLINE and EMBASE were searched from
inception to April 2013. Given the overlap between AS
and aortic sclerosis and the varying deﬁnitions of ASc, we
elected to use a broad search strategy including both aortic
sclerosis and AS that focused on incidence, prevalence,
progression, or outcomes (the exact search terms used are
listed in the Online Appendix). We eliminated those that
focused solely on AS in the subsequent search. No language
restrictions were used. Conference proceedings were not
excluded.
Citation details and abstracts were stored in a database
(FileMaker Pro 11.0v4, FileMaker, Santa Clara, California).
Initially, titles alone were reviewed for suitability. The ab-
stracts of suitable titles were obtained, and these were then
reviewed for suitability for full-text retrieval. Data were then
extracted as described in the following text from suitable
full-text reports. Additional appropriate reports were added
when discovered by citation tracking.
Inclusion and exclusion criteria. We designed a relatively
strict set of inclusion and exclusion criteria and considered
studies meeting these criteria to be of acceptable quality. Any
population-based study that examined ASc was included.
ASc was considered to mean any thickening or calciﬁcation
of the aortic valve without signiﬁcant hemodynamic effect
and could be diagnosed by any means, such as TTE,
transesophageal echocardiography, or CT. Electron beam
and multidetector CT were treated similarly for the purposes
of this review. Only studies with prospective enrollment
were included. Most of the studies performed off-line
retrospective image analysis; these were included as long as
the studies had prospective enrollment and image acquisition.
Hospital- or patient group–speciﬁc studies were excluded,
with the exception of studies performed in hypertensive
patients. Studies that focused solely on congenital valve
disease, including bicuspid aortic valves, were excluded.
Data extracted. In addition to publication details, we
extracted details about the number of participants, the age
and sex distribution of the population examined, the means
of diagnosing ASc, and, as appropriate, the prevalence,
incidence, or progression of ASc, along with the deﬁnitionof progression. For outcome
studies, we extracted the deﬁni-
tion of the type of event, the
crude event rate in the ASc
group and the control group, and
the adjusted risk due to ASc. We
also extracted the type of risk
ratio and how the risk ratio
was adjusted. The authors of re-
ports without full datasets were
contacted in an effort to gather
any required information not
reported.
Statistical methods. The dif-
ferences between the ages of
the participants in the studies
precluded meaningful meta-
analysis of the data on prevalence, incidence, and progres-
sion. To conﬁrm the link between age and prevalence,
we used linear regression to examine the association
between the average age reported in the study and the
prevalence of ASc (Stata version 12.1, StataCorp, College
Station, Texas).
We wished to meta-analyze the information on adverse
outcomes, in particular coronary events, stroke, cardiovas-
cular mortality, and all-cause mortality. Given the expected
heterogeneity between studies with regard to diagnostic
criteria and deﬁnition of outcomes, we used a random effects
model. The DerSimonian and Laird model with inverse
variance weights was used to combine hazard and risk ratios
using RevMan version 5.2.5 (11).
Results
Systematic review. Figure 1 shows the results of the search
strategy. Automated duplicate identiﬁcation was inefﬁcient,
leading to a number of duplicates identiﬁed only after ab-
stract review. Twenty-two reports were retrieved for data
extraction and form the basis of the results.
Prevalence. Nineteen reports were identiﬁed that examined
the prevalence of ASc (Table 1) (9,12–29). In all TTE-
based studies, ASc was diagnosed on the basis of increased
thickening and/or echogenicity, with a variable maximal
transvalvular velocity (indicated in Table 1) used to differ-
entiate aortic sclerosis from AS. In the Cardiovascular
Health Study, 2 different criteria were used, 2.5 and 2.0 m/s,
but the second of these was used only in a supplemental
cohort of 687 participants (8,22). Two reports from the
Framingham Offspring Study were included, because ASc
was diagnosed by different methods (14,23). The association
with age seen within studies was also seen across studies
(Fig. 2), with an 1.5% increase in prevalence per year of in-
crease in the mean age of study participants (95% conﬁdence
interval [CI]: 0.75% to 2.25%; p ¼ 0.0007, R2 ¼ 0.549).
Studies in which the mean age of the participants was
younger than 60 years had low levels of ASc, with all but 2 of
Figure 1 Results of Search Strategy
AS ¼ aortic stenosis.
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2854these studies showing <10% prevalence (13,21,23–26).
Figure 2 shows relatively similar prevalence for all of the
diagnostic modalities used.
Incidence. Five reports documented the incidence of ASc
(Table 2) (12,15,17,22,30). A clear difference was found
between CT- and TTE-based methods, with a yearly inci-
dence of 1.7% to 4.1% with CT-based diagnosis compared
with 7.5% to 8.8% with TTE-based diagnosis.
Progression. Five reports examined the progression of ASc
(Table 3) (12,15,17,22,30), with 3 of these focusing on
imaging outcomes and 2 on progression to clinical AS. In
total, 1.8% to 1.9% of subjects with ASc progressed to
clinical AS per year (15,22).
Risks. Six reports related baseline ASc to risk of death and
major adverse cardiovascular events (8,9,19,24,25,27). De-
tails of the studies are shown in Table 4, with the individual
adverse event type and associated risk ratios shown in
Table 5. A higher absolute event rate in subjects with ASc
was evident across all event categories, with reduction of the
risk once traditional cardiovascular risk factors were taken
into account.
There was a statistically signiﬁcant association with in-
creased coronary risk in subjects with ASc in 3 of the 4
studies (8,24,27), although one study showed a non–statis-
tically signiﬁcant increase (9). The latter study included a
coronary artery calcium (CAC) score in the fully adjusted
model (9), and the model with all other cardiovascular risk
factors but without CAC showed a statistically signiﬁcant
increase in coronary events, with a hazard ratio (HR) of 1.72(95% CI: 1.19 to 2.49). Whether the other studies would
have retained statistical signiﬁcance if CAC had been
included as a covariate is not clear; it is certain that there is a
strong link between coronary and valvular calciﬁcation (9).
Our meta-analysis showed a combined HR of 1.68 (95% CI:
1.31 to 2.15), with, as might be expected, substantial het-
erogeneity between results (I2 ¼ 62%) (Fig. 3).
All of the studies that reported stroke as an outcome
showed a small but not statistically signiﬁcant increase in
the risk of stroke in subjects with ASc (8,9,25). The meta-
analysis of these results showed a statistically signiﬁcant
increase in stroke, with an HR of 1.27 (95% CI: 1.01 to
1.60) and no detectable heterogeneity (I2 ¼ 0%).
There was a statistically signiﬁcant increased risk of both
cardiovascular and all-cause mortality in subjects with ASc
(8,9,19). After full adjustment, subjects with ASc had a risk
of dying from any cause that was 36% higher than that of
those without ASc (HR: 1.36; 95% CI: 1.17 to 1.59),
although the risk of cardiovascular death was 69% higher
(HR: 1.69; 95% CI: 1.32 to 2.15). Notably, in the study by
Owens et al. (9), the increased cardiovascular mortality
remained even after adjusting for CAC. No detectable
heterogeneity was seen for either cardiovascular or all-cause
mortality (I2 ¼ 0% for both).
Discussion
In this systematic review and meta-analysis, we compre-
hensively described the current epidemiology of ASc. As
Table 1 Prevalence of Aortic Valve Sclerosis
First Author (Ref.#) (Year)
Number of
Participants
Method of
Diagnosis Population Age, yrs* Female, % Prevalence, %
Messika-Zeitoun et al. (15)
(2007)
262 CT Randomly selected American subjects without
previous cardiac procedure (ECAC Study)
68  5 57 27
Thanassoulis et al. (14)
(2010)
1,323 CT Healthy American subjects (Framingham
Offspring Study)
64  9 52 39
Kaelsch et al. (13) (2011) 4,083 CT Randomly selected German subjects
(Heinz Nixdorf Recall Study)
59.4  7.7 51 11.2
Kearney et al. (12) (2012) 3,149 CT Randomly selected Icelandic subjects
(AGES-Reykjavik Study)
75  5 58 43
Owens et al. (9) (2012) 6,685 CT American subjects free of cardiovascular
disease at baseline (MESA)
62  10 53 13.4
Agmon et al. (16) (2001) 381 TEEy Randomly selected American subjects
(SPARC Study)
67 (51; 101) 48 35.4
Sverdlov et al. (17) (2012) 204 TTE
backscatter
Randomly selected Australian subjects 63  6 57.6 17.6
Lindroos et al. (29) (1993) 552 TTEy Randomly selected Finnish subjects
(Helsinki Ageing Study)
Number of participants
in each age group:
55–71 yrs, 76;
75–76 yrs, 197;
80–81 yrs, 155;
85–86 yrs, 124.
71.4 39.7
Gotoh et al. (28) (1995) 784 TTEz Subjects 35 years of age and older who were
residents of a single village in Japan
61.9  10.6 55.7 18.2
Aronow et al. (27) (1999) 2,358 TTEx American subjects who were residents of a
long-term care facility without terminal
illness
81  8 68.4 41.6
Taylor et al. (24) (2005) 2,279 TTEy African-American subjects free of
cardiovascular disease (ARIC Study)
59.1  5.6 65 7.7
Kizer et al. (25) (2005) 2,723 TTEy Native American subjects without
cardiovascular disease (Strong Heart Study)
59.2  7.7 64.9 7.5
Agno et al. (26) (2005) 1,624 TTEz Hypertensive American subjects (Hypertension
Genetic Epidemiology Network Study)
54  11 64.9 9.4
Fox et al. (23) (2006) 3,047 TTEy Healthy American subjects (Framingham
Offspring Study)
59  10 52 6.2
Novaro et al. (22) (2007) 5,621 TTEzk Randomly selected Medicare-eligible
American
subjects (Cardiovascular Health Study)
72.9  5.5 57.5 29
Stritzke et al. (21) (2009) 953 TTEy Randomly selected German subjects
(KORA/MONICA study)
57.7  11.7 52 28
Völzke et al. (19) (2010) 2,081 TTEy German subjects free of cardiovascular
disease and cancer (SHIP Study)
Women: 60 (53–68)
Men: 61 (54–69)
51.1 25.4
Sashida et al. (20) (2010) 2,085 TTEy American subjects free of stroke
(Northern Manhattan Study)
68.2  9.7 60 51.7
Lowery et al. (18) (2012) 3,010 TTE{ Healthy volunteers from the United Kingdom 60 NR 2.33
*Values are mean  SD, mean (minimal; maximal), median (interquartile range), or minimal. yNo maximal transvalvular velocity speciﬁed. zMaximal transvalvular velocity <2.0 m/s. xMaximal transvalvular
velocity <1.5 m/s. kMaximal transvalvular velocity <2.5 m/s. {Full description of diagnostic criteria not reported.
AGES ¼ Age, Gene-Environment Susceptibility; ARIC ¼ Atherosclerosis Risk in Communities; CT ¼ computed tomography; ECAC ¼ Epidemiology of Coronary Artery Calciﬁcation; KORA/MONICA ¼
Cooperative Research in the Region of Augsburg/Monitoring of Trends and Determinations in Cardiovascular Disease-Augsburg; MESA ¼ Multi-Ethnic Study of Atherosclerosis; NR ¼ not reported; SHIP ¼
Study of Health in Pomerania; SPARC ¼ Stroke Prevention: Assessment of Risk in a Community; TEE ¼ transesophageal echocardiography; TTE ¼ transthoracic echocardiography.
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2855expected, there was a clear increase in the prevalence of ASc
with increasing age of the population surveyed, which
makes ASc, similar to more advanced CAVD, a modern
problem related to an aging population.
The rate of incident ASc was relatively high even in
younger age groups, with 1.7% of those with normal aortic
valves at baseline developing ASc per year in a population
with a mean age of 61 years (30) and 9% with a mean age
of 72 years developing some degree of CAVD per year
(22). There was a difference in incidence measured by
different diagnostic modalities, and it is likely that thelower sensitivity of TTE compared with CT led to a larger
number of subjects with undetected CAVD at baseline in
the TTE-based studies. Although lack of a diagnostic gold
standard makes direct comparison difﬁcult, CT-based
diagnosis of AVC and echocardiographic diagnosis of
ASC both appear to represent the same disease process.
Using any AVC detected by CT as the criteria for diagnosis
of ASc leads to a higher prevalence of ASc, but still with
67% agreement between the 2 modalities, whereas higher
cutoffs for AVC lead to progressively lower estimates of
prevalence (31,32).
Figure 2 Prevalence of Aortic Sclerosis According to the Average Age of the Participants in the Study
The average age was either the mean or median according to the study report, and 2 studies without these data are not shown in the ﬁgure. The area of each data point is
proportional to the number of study participants. The straight line indicates the linear regression line ﬁtted, which showed a 1.5% (95% conﬁdence interval: 0.75% to 2.25%)
increase in prevalence for every year increase in average age (p ¼ 0.0007, R2 ¼ 0.549). CT ¼ computed tomography; TEE ¼ transesophageal echocardiography; TTE ¼
transthoracic echocardiography.
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2856The overall rate of progression of aortic sclerosis to AS
was low: <2% per year. Medical therapies such as statins
have shown no beneﬁt with regard to slowing or halting the
progression of AS (33–35), raising the possibility that the
intervention came at a stage too late in the disease process
(36). However the low rate of progression of ASc means
more reﬁned predictors of progression will be required to
adequately target those who might beneﬁt from disease-
modifying therapies. Interestingly, in contrast to de novoTable 2 Incidence of Aortic Valve Sclerosis
First Author (Ref. #)
(Year)
Number of
Participants
Method of
Diagnosis Population
Messika-Zeitoun
et al. (15) (2007)
192 CT Randomly selected Am
subjects without prev
cardiac procedure (E
Novaro et al. (22)
(2007)
3,917 TTEy Randomly selected Me
eligible American su
(Cardiovascular Heal
Owens et al. (30)
(2010)
5,142 CT American subjects free
cardiovascular diseas
at baseline (MESA)
Kearney et al. (12)
(2012)
1,934 CT Randomly selected Ice
subjects (AGES-Reyk
Study)
Sverdlov et al. (17)
(2012)z
160 TTE
backscatter
Randomly selected
Australian subjects
*Values are mean  SD, mean, or median (minimal to maximal). yMaximal transvalvular velocity <2.0 or
204 participants without aortic sclerosis at baseline in the study by Ngo et al. (42).
Abbreviations as in Table 1.development of AVC, once calcium is detectable in the
aortic valve, traditional cardiovascular risk factors play much
less of a role. In 2 studies, age was not associated with rate of
progression (15,30), whereas higher diastolic blood pressure
was associated with a decreased rate of progression (30).
Baseline calciﬁcation score and male sex were associated
with a higher rate of progression in both studies. Biomarkers
such as calcium concentration and impaired platelet nitric
oxide responsiveness have been shown to be predictive ofAge,
yrs* Female, %
Follow-Up,
yrs*
Incidence
per Year, %
erican
ious
CAC Study)
67 (5) 60 3.8  0.9 2.6
dicare-
bjects
th Study)
72 (5) 60 5 8.8 (or 9 if
aortic stenosis
is included)
of
e
62 (10) 45.5 2.4  0.9 1.7
landic
javik
NR NR 5.3 (2.6–9.2) 4.1
63 (6) 58 4 7.5
2.5 m/s. zBaseline information for participants in the study by Sverdlov et al. (17) was taken from all
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2857progression of TTE backscatter, but these biomarkers
require further investigation before they can be considered
ready for clinical use (17).
One hypothesis to explain the low rate of progression is
that ASc is not in itself an early stage of CAVD but is
simply a marker of general vascular disease, with an attendant
increase in cardiovascular risk. Coronary disease is common
in patients with CAVD; in those with severe AS requiring
intervention, between 40% and 75% have concomitant cor-
onary artery disease (37). The studies examining coronary
events and cardiovascular death either excluded participants
with prior coronary disease or included it as a covariate. A
high rate of preclinical disease, as measured by CAC, is
still seen in participants with ASc; 82% had some CAC in
MESA (Multi-Ethnic Study of Atherosclerosis) compared
with 45% in participants without ASc (9). However the
increase in cardiovascular mortality seen even after ac-
counting for CAC indicates that, although there is sub-
stantial overlap with coronary disease, ASc is accompanied
by an additional risk. Similarly, the very low rate of pro-
gression to AS in subjects with normal valves supports the
idea of aortic sclerosis as a separate disease process. In the
study by Novaro et al. (22), only 1% of those with normal
valves developed AS over 5 years compared with 9% of
those with aortic sclerosis. None of those with normal
valves at baseline developed moderate or severe AS in the
study by Messika-Zeitoun et al. (15). Although a shorter
interval between imaging would be required to deﬁnitively
prove that all patients developing AS progress through
aortic sclerosis initially, it seems likely on the basis of these
studies that aortic sclerosis is indeed a necessary but not
sufﬁcient step to AS.
The link between adverse outcomes and ASc is seen
clearly in this review, with an increased risk in all reported
event types. How do event rates compare between those with
aortic sclerosis and those with AS? The SEAS (Simvastatin
and Ezetimibe in Aortic Stenosis) trial and other studies
have consistently shown increasing event rates with in-
creasing severity of AS (38–40). Most population-based
studies have too few participants with AS to allow mean-
ingful comparison between those with AS and those with
aortic sclerosis. The Cardiovascular Health Study is an
exception, which showed an all-cause mortality rate of
41.3% for participants with AS compared with 21.9% for
those with aortic sclerosis (including those with baseline
coronary disease) and 14.9% for those with normal valves
over 5 years of follow-up (8). Cardiovascular mortality
(19.6% vs. 10.1% vs. 6.1% for participants with AS, aortic
sclerosis, and normal valves, respectively), myocardial in-
farction (11.3% vs. 8.6% vs. 6.0%, respectively), and stroke
(11.6% vs. 8.0% vs. 6.3%, respectively) showed similar pat-
terns. Therefore, aortic sclerosis appears to confer an inter-
mediate risk between normal valves and stenotic valves.
A recent meta-analysis also reported on the risk of car-
diovascular events and mortality in patients with ASc and
found lower (but still present) risk of all-cause and
Table 4 Studies Examining Major Adverse Events in Participants With Aortic Sclerosis
First Author (Ref. #) (Year) n
Method of
Diagnosis Population Age, yrs* Female, %
Follow-Up,
yrs*
Adjustment in
Multivariate
Analysis
Otto et al. (8)
(1999)
4,073 (4,271
for coronary
events and
stroke)
TTEy Randomly selected Medicare-eligible
American subjects (Cardiovascular
Health Study); only those without
prevalent cardiovascular disease
are shown here
72.9  5.5 57.5 5 Age, sex, height, presence of hypertension, current smoking,
elevated LDL cholesterol level, presence of diabetes
Aronow et al. (27)
(1999)
1,980 TTEz American residents of a long-term care
facility without terminal illness
81  8 68.4 3.8 (2.3) Age, prior coronary artery disease, sex
Taylor et al. (24)
(2005)
2,279 TTEx African-American subjects free of
cardiovascular disease (ARIC Study)
59.1  5.6 65 NR Age, sex, diabetes mellitus status, systolic blood pressure,
hypertension medication status, smoking status,
high-density lipoprotein level, carotid intimal-medial
thickness, ﬁbrinogen level, and von Willebrand factor level
Kizer et al. (25)
(2005)
2,273 TTEx Native American subjects without
cardiovascular disease at baseline
(Strong Heart Study)
59.2  7.7 65 7 Age and sex
Völzke et al. (19)
(2010)
2,081 TTEx German subjects free of cardiovascular
disease and cancer (SHIP Study)
Women: 60 (53–68)
Men: 61 (54– 69)
51.1 8.6 Age, sex, education, smoking status, diabetes mellitus,
serum LDL cholesterol level, use of antihypertensive
medication
Owens et al. (9)
(2012)
6,685 CT American subjects free of
cardiovascular disease at
baseline (MESA)
62  10 53 5.8 (5.6–5.9) Age, sex, race, body mass index, systolic and diastolic blood
pressure, diabetes status, use of antihypertensive
medication, smoking status, family history of heart attack,
total cholesterol level, high-density lipoprotein cholesterol
level, triglyceride level, use of cholesterol-lowering
medication, renal function, log (C-reactive protein),
log (coronary artery calcium score þ 1)
*Values are mean  SD, mean, or median (IQR). yMaximal transvalvular velocity <2.0 or 2.5 m/s. zMaximal transvalvular velocity <1.5 m/s. xNo maximal transvalvular velocity speciﬁed.
Abbreviations as in Table 1. LDL ¼ low-density lipoprotein.
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Table 5 Risk of Major Adverse Events in Participants With Aortic Sclerosis
First Author (Ref. #) (Year) Event Deﬁnition
Absolute Rate
per Year for Aortic
Sclerosis, %
Absolute Rate per
Year for Comparison
Group, %
Adjusted HR/RR
(95% CI)
Coronary events
Otto et al. (8) (1999) MI 1.6 0.9 RR: 1.40 (1.07–1.83)
Aronow et al. (27) (1999) New coronary events: fatal or nonfatal MI, SCD 13.9 8.16 RR: 1.76 (1.52–2.03)
Taylor et al. (24) (2005) Deﬁnite or probable hospitalized MI, ECG evidence of silent
MI, deﬁnite CAD death, CABG/PCI
NR NR HR: 3.82 (1.83–7.97)
Owens et al. (9) (2012) MI, resuscitated cardiac arrest, cardiovascular death 6.9 1.9 HR: 1.41 (0.98–2.02)
Stroke
Otto et al. (8) (1999) Fatal and nonfatal stroke 1.6 1.0 RR: 1.25 (0.96–1.64)
Kizer et al. (25) (2005) Fatal and nonfatal stroke 0.49 0.45 IRR: 1.15 (0.45–2.94)*
Owens et al. (9) (2012) Fatal and nonfatal stroke 3.6 1.2 HR: 1.38 (0.84–2.27)
Cardiovascular mortality
Otto et al. (8) (1999) Death from cardiac causes 1.4 0.6 RR: 1.52 (1.12–2.05)
Völzke et al. (19) (2010) Cardiovascular death 1.0 0.21 HR: 1.87 (1.12–3.11)
Owens et al. (9) (2012) Cardiovascular death excluding fatal stroke 0.38 0.05 HR: 2.51 (1.22–5.21)
All-cause mortality
Otto et al. (8) (1999) 3.7 1.9 RR: 1.35 (1.12–1.61)
Völzke et al. (19) (2010) 2.51 0.76 HR: 1.40 (1.06–1.85)
*The IRR and 95% CI reported by Kizer et al. (25) are not statistically consistent, and the true ﬁgure is likely to be an IRR of 1.15 (95% CI: 0.45 to 2.94).
Abbreviations as in Table 1. CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; CI ¼ conﬁdence interval; ECG ¼ electrocardiographic; HR ¼ hazard ratio; IRR ¼ incidence rate ratio;
MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; RR ¼ risk ratio; SCD ¼ sudden cardiac death.
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2859cardiovascular mortality, although the additional risk of
stroke was not statistically different (41). It is likely that the
patient subgroups included had a higher baseline risk, where
the additional risk due to ASc is not as evident. We excluded
many of the studies used in that meta-analysis because ofFigure 3 Forest Plot of Major Adverse Events According to the Pres
ASc ¼ aortic sclerosis; CI ¼ conﬁdence interval; IV ¼ inverse variance; Random ¼ randononprospective enrollment or restriction to a particular dis-
ease subgroup, such as those with advanced renal disease. In
addition, we included a study that the authors of that meta-
analysis identiﬁed but did not use (19) and included the ﬁrst
report from the Cardiovascular Health Study, which usedence of ASc
m effects model.
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2860echocardiography from an earlier time point in the study,
thereby reducing the risk of survivorship bias (8). Although
no statistically signiﬁcant increase in the risk of stroke was
seen in the individual studies, our meta-analysis showed a
27% increased risk of stroke in those with ASc compared
with those with normal aortic valves (HR: 1.27; 95% CI:
1.01 to 1.60). The meta-analysis was performed on ratios
obtained after adjusting for other risk factors, so the presence
of ASc appears to be an independent risk factor for major
adverse events. Whether any current or future treatments
will directly alter this risk remains to be tested, but in the
meantime, these results imply that aggressive investigation
and evidence-based treatment of other cardiovascular risk
factors should be performed in all people with ASc and at
least 5-year life expectancy.
Study limitations. Some of the limitations to this study are
common to other meta-analyses, such as heterogeneity bet-
ween study populations, deﬁnitions of exposure, and deﬁnitions
of outcomes. For example, a number of these studies were
conducted with ethnically homogeneous populations; the
ARIC (Atherosclerosis Risk in Communities) study exam-
ined African-American subjects (24), the AGES (Age,
Gene-Environment Susceptibility)-Reykjavik Study exam-
ined Icelandic subjects (12), and the Strong Heart Study
examined Native American subjects (25), whereas the Fra-
mingham Offspring Study consisted predominantly of
white American subjects of European descent (14). Differ-
ences in the deﬁnition of exposure are predominantly
attributable to the imaging modality used to diagnose ASc,
as discussed in the preceding text. Prevalence and progres-
sion rates were relatively consistent despite these differences
in the included studies. Differences in deﬁnitions of out-
comes, as shown in Table 5, are also a potential source of
heterogeneity between studies. Finally, another limitation
was the small number of studies reporting outcomes, in
particular cardiovascular and all-cause mortality, limiting
the ability to detect heterogeneity for coronary heart disease,
stroke, cardiovascular disease, and all-cause mortality. Des-
pite these caveats, the risk associated with ASc was re-
markably consistent across studies.
Conclusions
ASc is common in the general population, increases in
prevalence with the mean age of the population, and has a
low rate of progression to AS. Despite this, it is indepen-
dently associated with an increased risk of coronary events,
stroke, cardiovascular mortality, and all-cause mortality.
Investigation into whether these risks for ASc are modiﬁable
is warranted.
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APPENDIX
For the list of search terms used for the review, please see the online
version of this article.
